BI/Pfizer’s Spiriva Shows Bronchodilator Effect, Not Dyspnea, Cmte. Says

Boehringer Ingelheim/Pfizer's Spiriva demonstrates a clinically meaningful bronchodilator effect when used to treat chronic COPD patients, FDA's Pulmonary-Allergy Drugs Advisory Committee unanimously agreed Sept. 6